

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
9 October 2003 (09.10.2003)

PCT

(10) International Publication Number  
**WO 2003/082255 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 31/00,**  
A61P 29/02, A61K 38/00

Chuanzheng [CN/US]; 87 Reinman Road, Warren, NJ  
07059 (US). WEILER, Jan [DE/DE]; Binzener Strasse  
5b, 79539 Loerrach (DE). WISHART, William [US/CH];  
LeonardNeuweilerstrasse 16, CH-4123 Allschwil (CH).

(21) International Application Number:  
PCT/EP2003/003469

(22) International Filing Date: 2 April 2003 (02.04.2003)

(74) Agent: GROS, Florent; Novartis AG, Corporate Intellec-  
tual Property, Patent & Trademark Department, CH-4002  
Basel (CH).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/369,893 3 April 2002 (03.04.2002) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH,  
PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT,  
UA, US, UZ, VC, VN, YU, ZA, ZW.

(71) Applicant (*for all designated States except AT, US*): NO-  
VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel  
(CH).

(84) Designated States (*regional*): Eurasian patent (AM, AZ,  
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,  
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,  
IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(71) Applicant (*for AT only*): NOVARTIS PHARMA GMBH  
[AT/AT]; Brunner Strasse 59, 1230 Vienna (AT).

(72) Inventors; and

Published:

(75) Inventors/Applicants (*for US only*): BARCLAY, Jane  
[GB/GB]; Novartis Institute for Medical Sciences, 5 Gower  
Place, London WC1E 6BN (GB). BUXTON, Francis,  
Paul [GB/US]; 6 Applewood Lane, Morristown, NJ 07960  
(US). GANJU, Pamposh [GB/GB]; Novartis Institute  
for Medical Sciences, 5 Gower Place, London WC1E  
6BS (GB). NATT, Francois, Jean-Charles [FR/CH];  
Traugott Meyer-Strasse 5, CH-4147 Aesch (CH). SONG,

— with international search report

(88) Date of publication of the international search report:  
5 February 2004

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: USE OF MOB-5 IN PAIN

(57) Abstract: The invention discloses Mob-5 as a suitable target for the development of new therapeutics to treat or ameliorate chronic pain. The invention relates to methods to treat and/or ameliorate chronic pain and pharmaceutical compositions therefor comprising modulators with inhibitory or stimulatory effect on Mob-5 activity and/or Mob-5 gene expression. The invention also relates to a method to identify compounds with therapeutic usefulness to treat chronic pain, comprising identifying compounds that can inhibit or stimulate Mob-5 activity and/or gene expression which can also reverse the pathological effects of chronic pain in vivo.